Skip to main content
. 2014 Sep 15;9(9):e107161. doi: 10.1371/journal.pone.0107161

Table 3. Indirect comparison of EGFR exon 19 deletion versus EGFR exon 21 L858R mutation in TKI therapy cohort in terms of HR for PFS.

TKI HR19/21 of TKIa for PFS (95% CI) P-value
Gefitinib 0.76 (0.47–1.21) 0.244
Erlotinib 0.53 (0.18–1.61) 0.264
Afatinib 0.49 (0.21–1.17) 0.108
Overall 0.59 (0.38–0.92) 0.019
a

HR19/21 of TKI represents HR19 exon deletion/exon 21 L858R mutation in TKI therapy cohort.

Abbreviations: CI  =  confidence interval; EGFR  =  epidermal growth factor receptor; HR  =  Hazard ratio; PFS  =  progression-free survival; TKI  =  tyrosine kinase inhibitor.